Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

被引：0

作者：

Atkins, Michael B. ^{[1
]}

Escudier, Bernard ^{[2
]}

Mcdermott, David F. ^{[3
]}

Burotto, Mauricio ^{[4
]}

Choueiri, Toni K. ^{[5
,6
]}

Hammers, Hans J. ^{[7
]}

Plimack, Elizabeth R. ^{[8
]}

Porta, Camillo ^{[9
]}

George, Saby ^{[10
]}

Powles, Thomas ^{[11
]}

Donskov, Frede ^{[12
,13
]}

Kollmannsberger, Christian K. ^{[14
]}

Grimm, Marc-Oliver ^{[15
]}

Tomita, Yoshihiko ^{[16
]}

Rini, Brian, I ^{[17
]}

Jiang, Ruiyun ^{[18
]}

Federov, Viktor ^{[18
]}

Lee, Chung-Wei ^{[18
]}

Desilva, Heshani ^{[18
]}

Tannir, Nizar M. ^{[19
]}

Motzer, Robert J. ^{[20
]}

机构：

[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[2] Gustave Roussy, Villejuif, France

[3] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[4] Bradford Hill Clin Res Ctr, Santiago, Chile

[5] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[6] Harvard Med Sch, Boston, MA USA

[7] UT Southwestern Kidney Canc Program, Dallas, TX USA

[8] Fox Chase Canc Ctr, Oreland, PA USA

[9] Univ Pavia, Pavia, Italy

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England

[12] Univ Hosp, Cesena, Italy

[13] Southern Denmark Univ Hosp, Vejle, Denmark

[14] British Columbia Canc Agcy, Abbotsford, BC, Canada

[15] Jena Univ Hosp, Jena, Germany

[16] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[17] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[18] Bristol Myers Squibb, Moreton, England

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2024年 / 29卷

关键词：

Nivolumab; Ipilimumab; CheckMate; 214; Advanced RCC; Favorable Risk;

D O I：

10.1093/oncolo/oyae181.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S17 / S18

页数：2

共 50 条

[1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Albiges, Laurence
Tannir, Nizar M.
Burotto, Mauricio
McDermott, David
Plimack, Elizabeth R.
Barthelemy, Philippe
Porta, Camillo
Powles, Thomas
Donskov, Frede
George, Saby
Kollmannsberger, Christian K.
Gurney, Howard
Grimm, Marc-Oliver
Tomita, Yoshihiko
Castellano, Daniel
Rini, Brian, I
Choueiri, Toni K.
Saggi, Shruti Shally
McHenry, M. Brent
Motzer, Robert J.
ESMO OPEN, 2020, 5 (06)
[2] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
Escudier, Bernard
Mcdermott, David F.
Burotto, Mauricio
Choueiri, Toni K.
Hammers, Hans J.
Plimack, Elizabeth R.
Porta, Camillo
George, Saby
Powles, Thomas
Donskov, Frede
Atkins, Michael B.
Kollmannsberger, Christian K.
Grimm, Marc-Oliver
Tomita, Yoshihiko
Rini, Brian I.
Jiang, Ruiyun
Desilva, Heshani
Lee, Chung-Wei
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363
[3] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Tannir, N. M.
Albiges, L.
Mcdermott, D. F.
Burotto, M.
Choueiri, T. K.
Hammers, H. J.
Barthelemy, P.
Plimack, E. R.
Portat, C.
George, S.
Donskov, F.
Atkins, M. B.
Gurney, H.
Kollmannsberger, C. K.
Grimm, M. -o.
Barrios, C.
Tomita, Y.
Castellano, D.
Gruenwald, V.
Rini, B. I.
Jiang, R.
Desilva, H.
Fedorov, V.
Lee, C. -w.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
[4] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Tannir, Nizar M.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael Anthony
McDermott, David F.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Bracarda, Sergio
Tykodi, Scott S.
Powles, Thomas
Rini, Brian I.
Tomita, Yoshihiko
McHenry, M. Brent
Mekan, Sabeen Fatima
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[5] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[6] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Tannir, N. M.
McDermott, D. F.
Burotto, M.
Choueiri, T. K.
Hammers, H. J.
Plimack, E. R.
Porta, C. G.
George, S.
Powles, T. B.
Donskov, F.
Gurney, H.
Kollmannsberger, C. K.
Grimm, M-O.
Tomita, Y.
Rini, B. I.
McHenry, M. B.
Lee, C-W.
Escudier, B.
ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
[7] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Albiges, L.
Tannir, N.
Burotto, M.
McDermott, D. F.
Plimack, E. R.
Barthelemy, P.
Porta, C. G.
Powles, T. B.
Donskov, F.
George, S.
Kollmannsberger, C.
Gurney, H.
Grimm, M-O.
Tomita, Y.
Castellano Gauna, D.
Rini, B. I.
Choueiri, T. K.
Saggi, S. S.
McHenry, M. B.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
[8] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Motzer, Robert
Rini, Brian, I
McDermott, David F.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael A.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Neiman, Victoria
Bracarda, Sergio
Tykodi, Scott S.
Barthelemy, Philippe
Leibowitz-Amit, Raya
Plimack, Elizabeth R.
Oosting, Sjoukje F.
Redman, Bruce
Melichar, Bohusiav
Powles, Thomas
Nathan, Paul
Oudard, Stephan
Pook, David
Choueiri, Toni K.
Donskov, Frede
Grimm, Marc-Oliver
Gurney, Howard
Heng, Daniel Y. C.
Kollmannsberger, Christian K.
Harrison, Michael R.
Tamita, Yoshihiko
Duran, Ignacio
Gruenwold, Viktor
McHenry, M. Brent
Mekan, Sabeen
Tannir, Nizar M.
LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
[9] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
Tannir, Nizar M.
Signoretti, Sabina
Choueiri, Toni K.
McDermott, David F.
Motzer, Robert J.
George, Saby
Powles, Thomas
Donskov, Frede
Tykodi, Scott S.
Pal, Sumanta K.
Gupta, Saurabh
Lee, Chung-Wei
McHenry, M. Brent
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[10] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767

← 1 2 3 4 5 →